Investigators from Rutgers Cancer Institute of New Jersey, New Jersey's only National Cancer Institute- Designated Comprehensive Cancer Center, led a collaborative study to examine the patterns of druggable oncogenic fusions in colon cancer specimens including microsatellite-stable and unstable (MSI) tumors.